Here it is copy/pasted. Thanks, zdubble17 COVID-19

New Post Public Reply Private Reply Replies (1) Message Board
PatiencePeople zdubble17 #64030
518
Here it is copy/pasted. Thanks, zdubble17

COVID-19 treatment: is there any hope for existing drugs?
Scientists around the world are actively working on a vaccine against the coronavirus SARS-Cov-2. At the same time, it is possible that existing drugs can help in the fight against this disease.

Scientists from different countries are looking for a medicine against COVID-19
To date, around 70 studies have begun and are underway on the creation of a vaccine against the coronavirus SARS-Cov-2 . However, even if it is developed already in 2020, it is unlikely that mass vaccination of the population will be possible in the near future. Therefore, so far there are, in fact, only two options for combating coronavirus: either prolonging the action of quarantine measures, or treating this disease with existing medicines .
Three groups of drugs against coronavirus
Currently, scientists are testing three groups of drugs that may be able to help patients with COVID-19. These are antiviral drugs, immunomodulators and respiratory agents.
Схематичное изображение вируса и легких человека
Antiviral drugs are designed to prevent the penetration of the virus into lung cells.
Antiviral drugs prevent the virus from entering the lung cells or prevent them from multiplying inside the cell. Such drugs are used to treat common flu, hepatitis C, as well as HIV infection, Ebola and, most importantly, SARS and Middle Eastern respiratory syndrome (MERS), which are also caused by coronaviruses.
The second group of drugs - immunomodulators - is used to limit the excessive reaction of the immune system, which in itself can become life-threatening. Such drugs, for example, are used in the treatment of arthritis or inflammatory bowel disease.
The third group includes drugs that allow the lungs to continue to supply the blood with enough oxygen. They are used, in particular, for the treatment of idiopathic pulmonary fibrosis, a pathological process in which connective tissue proliferates in the walls of the alveoli (pulmonary vesicles). Because of this, the patient suffers from a chronic lack of oxygen, he develops rapid breathing, shortness of breath and dry reflex cough.
Antiviral drugs Remdesivir and Avigan
One of the drugs that scientists have hopes for is the American antiviral drug Remdesivir, used in the treatment of Ebola, and also proved to be effective in combating SARS and MERS. Chinese experts are now trying to find out whether this medication can help in the fight against COVID-19. The first research results should be published in April.
Ампула с препаратом Remdesivir
Remdesivir is being tested in Hamburg
In the United States, similar studies were started by the University of Nebraska in Omaha, and the Pentagon, in its own trials, uses this drug to treat American military coronavirus. In addition, three German hospitals are going to test Remdesivir - in Munich, Dusseldorf and Hamburg.
The Japanese antiviral drug Avigan with the active ingredient favipiravir, which is used for severe forms of influenza, is also in the spotlight of specialists. The drug has also been used successfully in the treatment of Ebola. Scientists around the world are currently testing its effectiveness against COVID-19 . Christian Drosten, director of the Institute of Virology at the Charite Hospital in Berlin, called the preliminary research results encouraging. Despite the fact that the final conclusions are still far away, many countries have already turned to Japan with a request for the wholesale supply of this medication.
The effectiveness of antimalarial drugs is in question
Meanwhile, the German pharmaceutical concern Bayer AG is re-equipping factories in Europe for the release of the drug against malaria Resochin with the active substance chloroquine. The company plans not only to supply this medicine to German hospitals, but also to supply it free of charge to other countries. A clinical study conducted in a hospital in Marseille showed the effectiveness of chloroquine for the treatment of pneumonia COVID-19. So far, the medicine under the brand name Resochin has been produced only in Pakistan.

Meanwhile, Indian authorities have banned the export of another anti-malarial drug hydroxychloroquine. Experts in a number of countries are also testing it as a treatment for patients infected with coronavirus.
However, a number of virologists, including Christian Drosten of Charite, are not convinced of the reliability of the results of the Marseille study. The U.S. Department of Health and Human Services also made similar doubts after President Donald Trump spoke out in favor of using chloroquine and hydroxychloroquine in treating patients with COVID-19.
Medicines Against HIV, Cancer and MERS
Scientists admit that a combination of ritonavir and lopinavir, drugs used to suppress HIV replication, may also be effective. The drug "Kaletra" (the trade name for a combination of these substances) of the American pharmaceutical company AbbVie has already been used for experimental treatment of COVID-19 in China, Thailand and Singapore. The results of clinical tests, however, so far look unconvincing.
In addition, several other active substances that may be suitable for the treatment of coronavirus are also being tested. These include Leronlimab, which is used to treat patients with HIV and metastatic breast cancer, antibodies originally developed against MERS, and Brilacidin, which is used for inflammatory diseases of the intestines and oral mucosa.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 35

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Tony Perkins' Church Tour amid Controversial Vote

Updated Category News Views 89

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 63

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 89

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 136

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
COhatch Preps for High-Stakes Ohio Pitch Contest

Updated Category News Views 31

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....

Continue Reading
Chemours Faces Class Action Over Fraud Allegations

Updated Category News Views 206

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 112

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Gildan Faces Lawsuit: Allegations of Deceptive Practices Shake Investors

Updated Category News Views 192

Gildan's Troubles Unveiled The financial jungle can be a pretty treacherous place, and Gildan Activewear Inc. (NYSE: GIL) just found out how fickle the market can be. An 18.7% nosedive in Gildan's stock price after a securities fraud class action came knocking—if that isn't enough to stir up a hornet’s nest among investors, I don’t know what is. The Catalyst:...

Continue Reading
Lunit, Summit Tackle Tumor Analysis with AI Platform

Updated Category News Views 212

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Continue Reading

Top 5 Most Recently Viewed Articles

i3 Verticals' Strategic Shift Boosts Confidence in Future Growth

Updated Category News Views 53

i3 Verticals' Strategic Transformation Enhances Market Position i3 Verticals (NASDAQ: IIIV), recognized for providing integrated payment and software solutions, has recently received a boost in market confidence following the announcement of its significant $438 million divestiture. This strategic decision marks a pivotal moment for the company, allowing it to sharpen its...

Continue Reading
Understanding the Transformative Role of Placental Tissue for Healing

Updated Category News Views 93

Exploring the Benefits of Placental Allografts Marietta, GA – MiMedx Group, Inc. (NASDAQ: MDXG) has recently spotlighted the insights shared in a feature article about placental allografts, which focus on their application for healing complex wounds. This discussion surfaced through a compelling article in a major publication, highlighting the incredible advantages...

Continue Reading
Celebrate Impact: 13 Independent Coffee Shops Thriving Together

Updated Category News Views 326

Crimson Cup Supports Anniversaries of 13 Independent Coffee Shops Crimson Cup Coffee & Tea is proud to acknowledge the special anniversaries of 13 independent coffee houses this month. These remarkable shops are located in various states and have embraced their milestones, ranging from one year to an impressive 13 years of serving delicious coffee. The success these...

Continue Reading
Exploring Key UK Economic Trends Forecasted for 2025

Updated Category News Views 254

Insights on UK Economic Trends for 2025 The new year has arrived, and Deutsche Bank (ETR: DBKGn) has highlighted eight vital themes expected to influence the UK economy as we move further into 2025. Despite current uncertainties, analysts from Deutsche Bank express a level of optimism, indicating that government spending is likely to become a significant contributor to...

Continue Reading
Centene Corporation Reports Impressive Financial Results for 2024

Updated Category News Views 1146

Centene Corporation's Stellar 2024 Financial Overview Centene Corporation (NYSE: CNC) showcased robust financial performance for the year 2024, highlighted by a significant increase in diluted earnings per share (EPS) and revenue growth across various segments. The company's diluted EPS rose to $6.31, with an adjusted diluted EPS reaching $7.17, reflecting a 7% increase...

Continue Reading